
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k101251
B. Purpose for Submission:
Addition of 13 new allergens to a cleared device
C. Measurand:
Thirteen new allergen-specific IgE: nDer p 1, rDer p 2, rDer 10, rFel d 1, nFel d 2,
rAra h 1, rAra h 2, rAra h 3, rAra h 8, rAra h 9, nCyn d 1,rAlt a 1, and nAmb a 1
D. Type of Test:
Fluoroenzymeimmunoassay, Quantitative and Semi-quantitative
E. Applicant:
Phadia AB
F. Proprietary and Established Names:
ImmunoCAP Allergen d202, Allergen component nDer p 1, House dust mite
ImmunoCAP Allergen d203, Allergen component rDer p 2, House dust mite
ImmunoCAP Allergen d205, Allergen component rDer p 10, Tropomyosin, House
dust mite
ImmunoCAP Allergen e94, Allergen component rFel d 1, Cat
ImmunoCAP Allergen e220, Allergen component nFel d 2, Cat serum albumin
ImmunoCAP Allergen f422, Allergen component rAra h 1, Peanut
ImmnuoCAP Allergen f423, Allergen component rAra h 2, Peanut
ImmunoCAP Allergen f424, Allergen component rAra h 3, Peanut
ImmunoCAP Allergen f352, Allergen component rAra h 8, PR-10, Peanut
ImmunoCAP Allergen f427, Allergen component rAra h 9, LTP, Peanut
ImmunoCAP Allergen g216, Allergen component nCyn d 1, Bermuda grass
ImmunoCAP Allergen m229, Allergen component rAlt a 1, Alternaria alternata
ImmunoCAP Allergen w230, Allergen component nAmb a 1, Ragweed
G. Regulatory Information:
1. Regulation section:
21 CFR § 866.5750, Radioallergosorbent (RAST) immunological test system
2. Classification:
Class II
3. Product code:
DHB - System, Test, Radioallergosorbent (RAST), Immunological
4. Panel:
Immunology (82)
H. Intended Use:
1. Intended use(s):
ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of
allergen specific IgE in human serum or plasma. ImmunoCAP Specific IgE is to
be used with instruments Phadia 100, Phadia 250, and Phadia 1000. It is intended
for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated
1

--- Page 2 ---
allergic disorders in conjunction with other clinical findings, and is to be used in
clinical laboratories.
2. Indication(s) for use:
Same as intended use.
3. Special conditions for use statement(s):
For prescription use only
4. Special instrument requirements:
ImmunoCAP Specific IgE is to be used with the instrument Phadia 100 Phadia
250 and Phadia 1000
I. Device Description:
The ImmunoCAP system is a fully integrated and automated system for the
determination of specific IgE in human blood serum or plasma. It is comprised of
instrument Phadia 100, Phadia 250 and Phadia 1000 test system modules (comprising
general, test and method specific reagents), as well as instrument and data
management software. The ImmunoCAP reagents include ImmunoCAP specific IgE
Conjugate, ImmunoCAP Specific IgE Curve Control, ImmunoCAP Specific IgE
Calibrators, Specific IgE anti-IgE ImmunoCAP, Allergen ImmunoCAP carriers,
ImmunoCAP development solution and stop solution.
Individual allergen tests (the method specific reagents) are individual proteins
covalently coupled to a support in a plastic housing. Individual allergens are purified
native proteins or recombinantly produced and purified proteins.
J. Substantial Equivalence Information:
1. Predicate device name(s):
ImmunoCAP Specific IgE
2. Predicate K number(s):
k051218
3. Comparison with predicate:
Similarities
Item Device Predicate
Indications for Use ImmunoCAP Specific IgE is an in vitro Same
quantitative assay for the measurement
of allergen specific IgE in human serum
or plasma. It is intended for in vitro
diagnostic use as an aid in the clinical
diagnosis of IgE mediated allergic
disorders in conjunction with other
clinical findings, and is to be used in
clinical laboratories, as well as
physician office laboratories.
Number of calibrators Six Same
Sample matrix Serum and Plasma Same
Antibody β-Galactosidase-anti-IgE (mouse Same
monoclonal antibody) for all
ImmunoCAP
Basic principle Fluoroenzymeimmunoassay Same
2

[Table 1 on page 2]
Similarities								
	Item			Device			Predicate	
Indications for Use			ImmunoCAP Specific IgE is an in vitro
quantitative assay for the measurement
of allergen specific IgE in human serum
or plasma. It is intended for in vitro
diagnostic use as an aid in the clinical
diagnosis of IgE mediated allergic
disorders in conjunction with other
clinical findings, and is to be used in
clinical laboratories, as well as
physician office laboratories.			Same		
Number of calibrators			Six			Same		
Sample matrix			Serum and Plasma			Same		
Antibody			β-Galactosidase-anti-IgE (mouse
monoclonal antibody) for all
ImmunoCAP			Same		
Basic principle			Fluoroenzymeimmunoassay			Same		

--- Page 3 ---
Similarities
Item Device Predicate
Sample volume 40 µl Same
Process time 2 hours 30 minutes for Phadia 100. Same
1 hour 45 minutes for Phadia 250 and
1000.
Incubation temperature 37°C Same
Differences
Item Device Predicate
Modification Existing allergen tests consist of Existing allergen
multiple proteins from the tests are to whole
allergen source. The new devices allergens
are individual proteins from this comprising
mix. Some are purified native multiple proteins
proteins and some are from the allergen
recombinantly produced and source
purified. Recombinant proteins
are: rDer p 2, rDer 10, rFel d 1,
rAra h 1, rAra h 2, rAra h 3, rAra
h 8, rAra h 9, rAlt a 1
K. Standard/Guidance Document Referenced (if applicable):
CLSI I/LA20-A: Evaluation Methods and Analytical Performance Characteristics of
Immunological Assays for Human Immunoglobulin E (IgE) Antibodies of Defined
Allergen Specificities; Approved Guideline (1997) I/LA20-A.
CEN 13640: Stability Testing of in vitro Diagnostic Reagents.
CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of
Quantitation.
Radioallergosorbent Test (RAST) Methods for Allergen-Specific Immunoglobulin E
(IgE) 510(k)s; Final Guidance for Industry and FDA
L. Test Principle:
The allergen of interest covalently coupled to the ImmunoCAP solid phase, reacts
with the specific IgE in the patients plasma/serum sample. After washing away non
specific IgE, enzyme labeled antibodies against IgE are added to form a complex.
After incubation, unbound enzyme-anti-IgE is washed away and the bound complex
is then incubated with the developing agent. After stopping the reaction, the
fluorescence of the eluate is measured. The higher the response value, the more
specific IgE present in the specimen. To evaluate the rest results, the response for the
patient samples are transformed to concentrations with the use of a calibration curve.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Within-Lot imprecision:
Imprecision of the individual allergen components were tested by using two
3

[Table 1 on page 3]
Similarities								
	Item			Device			Predicate	
Sample volume			40 µl			Same		
Process time			2 hours 30 minutes for Phadia 100.
1 hour 45 minutes for Phadia 250 and
1000.			Same		
Incubation temperature			37°C			Same		

[Table 2 on page 3]
Differences							
	Item			Device		Predicate	
Modification			Existing allergen tests consist of
multiple proteins from the
allergen source. The new devices
are individual proteins from this
mix. Some are purified native
proteins and some are
recombinantly produced and
purified. Recombinant proteins
are: rDer p 2, rDer 10, rFel d 1,
rAra h 1, rAra h 2, rAra h 3, rAra
h 8, rAra h 9, rAlt a 1			Existing allergen
tests are to whole
allergens
comprising
multiple proteins
from the allergen
source	

--- Page 4 ---
plasma samples (0.35 ± 25% and ≥0.7 kU /l) tested four times per run, two
A
runs per day, for ten days (a total of 80 replicates per allergen). The studies
shown below were performed on a Phadia 250 instrument according to the
ImmunoCAP Specific IgE, Directions for Use. In data not shown here, the
applicant demonstrated similar assay precision on the Phadia 100 and Phadia
1000 instruments.
Allergen Group: House Dust Mite (Dermatophagoides pteronyssinus)
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
nDer p 1 0.34 0.66 3.12 2.91 4.31
d202
1.82 2.93 2.59 2.93 4.89
rDer p 2 0.33 2.02 2.46 2.35 3.96
d203
2.02 0.42 3.76 1.70 4.14
rDer 10 0.36 1.99 3.24 2.90 4.78
d205
2.36 1.86 4.67 2.23 5.50
Allergen Group: Cat (Felis catus)
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
0.33 0.00 2.89 3.21 4.32
rFel d 1 e94
2.58 0.00 6.53 1.98 6.82
nFel d 2 0.36 0.85 2.77 2.22 3.66
e220
2.14 1.85 1.91 2.24 3.48
Allergen Group: Peanut (Arachis hypogea)
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
0.35 0.66 3.82 1.90 4.32
rAra h 1 f422
1.96 5.43 3.82 1.65 6.84
0.31 3.83 4.03 10.05 11.49
rAra h 2 f423
2.82 2.62 6.48 7.04 9.92
rAra h 3 f424 0.36 1.49 2.76 6.04 6.80
4

[Table 1 on page 4]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
nDer p 1	d202	0.34	0.66	3.12	2.91	4.31
		1.82	2.93	2.59	2.93	4.89
rDer p 2	d203	0.33	2.02	2.46	2.35	3.96
		2.02	0.42	3.76	1.70	4.14
rDer 10	d205	0.36	1.99	3.24	2.90	4.78
		2.36	1.86	4.67	2.23	5.50

[Table 2 on page 4]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
rFel d 1	e94	0.33	0.00	2.89	3.21	4.32
		2.58	0.00	6.53	1.98	6.82
nFel d 2	e220	0.36	0.85	2.77	2.22	3.66
		2.14	1.85	1.91	2.24	3.48

[Table 3 on page 4]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
rAra h 1	f422	0.35	0.66	3.82	1.90	4.32
		1.96	5.43	3.82	1.65	6.84
rAra h 2	f423	0.31	3.83	4.03	10.05	11.49
		2.82	2.62	6.48	7.04	9.92
rAra h 3		0.36	1.49	2.76	6.04	6.80

--- Page 5 ---
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
3.47 1.49 3.10 3.17 4.68
0.37 0.67 1.65 2.11 2.76
rAra h 8 f352
2.55 0.00 3.49 3.97 5.29
0.33 1.80 2.82 1.99 3.90
rAra h 9 f427
2.35 6.03 5.02 2.38 8.20
Allergen Group: Bermuda grass (Cynodon dactylon)
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
0.35 1.93 1.88 2.25 3.51
rCyn d 1 g216
2.07 0.00 3.02 2.23 3.75
Allergen Group: Alternaria alternata
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
0.37 3.10 2.35 1.82 4.29
rAlt a 1 w230
2.32 2.16 2.60 2.27 4.07
Allergen Group: Ragweed (Ambrosia artemisiifolia)
Between Between runs
Component Mean Within run Total
Allergen days within day
Number (kU /l) CV% CV%
A
CV% CV%
0.35 1.58 3.05 1.89 3.92
nAmb a 1 m229
2.36 2.22 2.75 1.88 4.00
Lot-to-lot imprecision:
Three lots of each individual allergen were tested using two positive samples
(0.35 ± 25% and ≥0.7 kU /L) and one negative sample (< 0.1 kU /L). For
A A
each lot the samples were tested in 12 replicates in one assay run. Each lot
represented a different preparation of the allergen from routine production.
Allergen Group: House Dust Mite (Dermatophagoides pteronyssinus)
5

[Table 1 on page 5]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
		3.47	1.49	3.10	3.17	4.68
rAra h 8	f352	0.37	0.67	1.65	2.11	2.76
		2.55	0.00	3.49	3.97	5.29
rAra h 9	f427	0.33	1.80	2.82	1.99	3.90
		2.35	6.03	5.02	2.38	8.20

[Table 2 on page 5]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
rCyn d 1	g216	0.35	1.93	1.88	2.25	3.51
		2.07	0.00	3.02	2.23	3.75

[Table 3 on page 5]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
rAlt a 1	w230	0.37	3.10	2.35	1.82	4.29
		2.32	2.16	2.60	2.27	4.07

[Table 4 on page 5]
Allergen	Component
Number	Mean
(kU /l)
A	Between
days
CV%	Between runs
within day
CV%	Within run
CV%	Total
CV%
nAmb a 1	m229	0.35	1.58	3.05	1.89	3.92
		2.36	2.22	2.75	1.88	4.00

--- Page 6 ---
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
1 2.49 4.1 0.39 3.4 0.00
nDer p 1
2 2.73 6.0 0.40 4.9 0.00
(d202)
3 2.35 8.8 0.37 3.4 0.00
1 2.10 2.6 0.35 2.5 0.00
rDer p 2
2 2.27 2.9 0.38 1.8 0.00
(d203)
3 2.11 1.5 0.35 2.6 0.00
1 2.63 1.2 0.44 2.2 0.00
rDer 10
2 2.47 2.2 0.42 2.6 0.00
(d205)
3 2.58 2.0 0.41 2.2 0.00
Allergen Group: Cat (Felis catus)
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
1 3.10 1.7 0.40 3.3 0.00
rFel d 1
2 2.77 2.1 0.37 2.0 0.00
(e94)
3 3.07 2.7 0.40 1.8 0.00
1 2.16 1.9 0.33 2.0 0.00
nFel d 2
2 2.18 2.7 0.38 1.8 0.00
(e220)
3 2.15 1.5 0.37 2.8 0.00
Allergen Group: Peanut (Arachis hypogea)
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
1 2.35 1.4 0.41 1.2 0.00
rAra h 1
2 2.29 2.2 0.39 1.7 0.00
(f422)
3 2.23 2.6 0.39 2.5 0.00
rAra h 2 1 3.60 3.8 0.32 2.6 0.03
(f423)
2 3.27 4.5 0.29 3.5 0.03
6

[Table 1 on page 6]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A
nDer p 1
(d202)	1	2.49	4.1	0.39	3.4	0.00
	2	2.73	6.0	0.40	4.9	0.00
	3	2.35	8.8	0.37	3.4	0.00
rDer p 2
(d203)	1	2.10	2.6	0.35	2.5	0.00
	2	2.27	2.9	0.38	1.8	0.00
	3	2.11	1.5	0.35	2.6	0.00
rDer 10
(d205)	1	2.63	1.2	0.44	2.2	0.00
	2	2.47	2.2	0.42	2.6	0.00
	3	2.58	2.0	0.41	2.2	0.00

[Table 2 on page 6]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A
rFel d 1
(e94)	1	3.10	1.7	0.40	3.3	0.00
	2	2.77	2.1	0.37	2.0	0.00
	3	3.07	2.7	0.40	1.8	0.00
nFel d 2
(e220)	1	2.16	1.9	0.33	2.0	0.00
	2	2.18	2.7	0.38	1.8	0.00
	3	2.15	1.5	0.37	2.8	0.00

[Table 3 on page 6]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A
rAra h 1
(f422)	1	2.35	1.4	0.41	1.2	0.00
	2	2.29	2.2	0.39	1.7	0.00
	3	2.23	2.6	0.39	2.5	0.00
rAra h 2
(f423)	1	3.60	3.8	0.32	2.6	0.03
	2	3.27	4.5	0.29	3.5	0.03

--- Page 7 ---
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
3 2.99 6.6 0.26 2.9 0.02
1 3.77 3.1 0.32 1.9 0.00
rAra h 3
2 3.81 1.8 0.34 2.6 0.00
(f424)
3 4.06 2.8 0.34 3.7 0.00
1 2.57 4.1 0.33 1.9 0.00
rAra h 8
2 2.44 5.1 0.32 2.3 0.00
(f352)
3 2.70 3.6 0.33 1.9 0.00
1 2.85 3.5 0.38 2.1 0.00
rAra h 9
2 3.00 3.7 0.39 1.9 0.00
(f427)
3 2.53 1.9 0.34 1.2 0.00
Allergen Group: Bermuda grass (Cynodon dactylon)
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
1 1.78 4.5 0.37 2.7 0.00
nCyn d 1
2 2.19 2.1 0.39 3.4 0.00
(g216)
3 2.16 2.8 0.38 2.3 0.00
Allergen Group: Alternaria alternata
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
1 2.30 1.8 0.37 2.2 0.00
rAlt a 1
2 2.28 2.2 0.37 2.1 0.00
(w230)
3 2.24 2.0 0.36 1.5 0.00
Allergen Group: Ragweed (Ambrosia artemisiifolia)
Sample
Allergen Positive 1 Positive 2 Negative
Lot
(Component number) Mean CV Mean CV Mean
(kU /l) (%) (kU /l) (%) (kU /l)
A A A
7

[Table 1 on page 7]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A
	3	2.99	6.6	0.26	2.9	0.02
rAra h 3
(f424)	1	3.77	3.1	0.32	1.9	0.00
	2	3.81	1.8	0.34	2.6	0.00
	3	4.06	2.8	0.34	3.7	0.00
rAra h 8
(f352)	1	2.57	4.1	0.33	1.9	0.00
	2	2.44	5.1	0.32	2.3	0.00
	3	2.70	3.6	0.33	1.9	0.00
rAra h 9
(f427)	1	2.85	3.5	0.38	2.1	0.00
	2	3.00	3.7	0.39	1.9	0.00
	3	2.53	1.9	0.34	1.2	0.00

[Table 2 on page 7]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A
nCyn d 1
(g216)	1	1.78	4.5	0.37	2.7	0.00
	2	2.19	2.1	0.39	3.4	0.00
	3	2.16	2.8	0.38	2.3	0.00

[Table 3 on page 7]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A
rAlt a 1
(w230)	1	2.30	1.8	0.37	2.2	0.00
	2	2.28	2.2	0.37	2.1	0.00
	3	2.24	2.0	0.36	1.5	0.00

[Table 4 on page 7]
Allergen
(Component number)	Lot	Sample				
		Positive 1		Positive 2		Negative
		Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A	CV
(%)	Mean
(kU /l)
A

--- Page 8 ---
1 2.52 2.1 0.39 1.4 0.00
nAmb a 1
2 2.33 1.6 0.37 2.2 0.00
(m229)
3 2.52 2.3 0.40 2.6 0.00
b. Linearity/assay reportable range:
The linearity of the 13 individual allergens was assessed by diluting three
positive plasma samples per allergen in negative plasma to provide at least
five 2-fold consecutive dilutions. Undiluted and diluted samples were tested in
four replicates in one assay run. The assay was performed according to the
ImmunoCAP Specific IgE, Directions for Use using instrument Phadia 250.
For each product one lot of ImmunoCAP Allergen Component was used. The
ImmunoCAP Specific Total IgE working range is LoD – 100 kUA/l.
For each allergen, the replicates from all three samples were pooled and
analyzed for linearity. Regression statistics for each allergen comparing the
observed results to expected results are presented below:
Allergen Group: House Dust Mite (Dermatophagoides pteronyssinus)
Allergen
95% CI 95% CI
(Component Regression Equation R2
Slope Intercept
Number)
nDer p 1
y = 0.99x + 0.04 0.99 0.97 – 1.00 0.04 – 0.02
(d202)
rDer p 2
y = 1.00x 1.00 0.99 – 1.01 -0.01 – 0.01
(d203)
rDer 10
y = 1.00x + 0.03 1.00 0.97 – 1.02 0.01 – 0.05
(d205)
Allergen Group: Cat (Felis catus)
Allergen
95% CI 95% CI
(Component Regression Equation R2
Slope Intercept
Number)
rFel d 1
y = 0.97x +0.03 0.99 0.95 – 0.98 0.02 – 0.04
(e94)
nFel d 2
y = 0.94x + 0.08 0.99 0.93 – 0.96 0.06 – 0.09
(e220)
Allergen Group: Peanut (Arachis hypogea)
8

[Table 1 on page 8]
nAmb a 1
(m229)	1	2.52	2.1	0.39	1.4	0.00
	2	2.33	1.6	0.37	2.2	0.00
	3	2.52	2.3	0.40	2.6	0.00

[Table 2 on page 8]
Allergen
(Component
Number)	Regression Equation	R2	95% CI
Slope	95% CI
Intercept
nDer p 1
(d202)	y = 0.99x + 0.04	0.99	0.97 – 1.00	0.04 – 0.02
rDer p 2
(d203)	y = 1.00x	1.00	0.99 – 1.01	-0.01 – 0.01
rDer 10
(d205)	y = 1.00x + 0.03	1.00	0.97 – 1.02	0.01 – 0.05

[Table 3 on page 8]
Allergen
(Component
Number)	Regression Equation	R2	95% CI
Slope	95% CI
Intercept
rFel d 1
(e94)	y = 0.97x +0.03	0.99	0.95 – 0.98	0.02 – 0.04
nFel d 2
(e220)	y = 0.94x + 0.08	0.99	0.93 – 0.96	0.06 – 0.09

--- Page 9 ---
Allergen
95% CI 95% CI
(Component
Regression Equation R2
Slope Intercept
Number)
rAra h 1
y = 1.00x - 0.05 1.00 1.00 – 1.01 -0.05 - -0.04
(f422)
rAra h 2
y = 0.91x + b0.09 0.99 0.90 – 0.93 0.08 – 0.11
(f423)
rAra h 3
y = 0.99x + 0.02 0.99 0.96 – 1..01 0 – 0.04
(f424)
rAra h 8
y =1.00x 1.00 0.99 – 1.01 -0.01 – 0.01
(f352)
rAra h 9
y = 1.01x – 0.03 1.00 1.00 – 1.03 -0.04 - -0.02
(f427)
Allergen Group: Bermuda grass, Alternaria alternata, and Ragweed
Allergen
95% CI 95% CI
(Component
Regression Equation R2
Slope Intercept
Number)
nCyn d
y = 0.96 1.00 0.95 – 0.97 0.04 – 0.05
(g216)
rAlt a 1
y = 0.96x 0.99 0.96 – 0.99 -0.01 – 0.01
(m229)
nAmb a 1
y = 0.97x + 0.02 1.00 0.96 – 0.98 0.02 – 0.03
(w230)
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
The IgE calibrators are traceable (via an unbroken chain of calibrations) to the
2nd International Reference Preparation (IRP) 75/502 of Human Serum
Immunoglobulin E from World Health Organization (WHO).
Real-time stability study results were available for rFel d 1, nFel d 2, rAlt a 1,
rAra h 1, rAra h 2, rAra h 3 and rAra h 8 PR-10 and support an unopened
shelf-life of 24 months from the date of manufacture when stored at 2-8°C.
For the real-time study, more than one lot of each component allergen was
stored at 2-8°C. At different times a positive and a negative plasma sample
were tested in three replicates in one assay; the results were compared to the
results of the same samples tested at time = 0.
Accelerated stability studies performed on allergen components nDer p 1,
rDer p 2, rDer 10, nAmb a 1, nCyn d 1, and rAra h 9 LTP support an
9

[Table 1 on page 9]
Allergen
(Component
Number)	Regression Equation	R2	95% CI
Slope	95% CI
Intercept
rAra h 1
(f422)	y = 1.00x - 0.05	1.00	1.00 – 1.01	-0.05 - -0.04
rAra h 2
(f423)	y = 0.91x + b0.09	0.99	0.90 – 0.93	0.08 – 0.11
rAra h 3
(f424)	y = 0.99x + 0.02	0.99	0.96 – 1..01	0 – 0.04
rAra h 8
(f352)	y =1.00x	1.00	0.99 – 1.01	-0.01 – 0.01
rAra h 9
(f427)	y = 1.01x – 0.03	1.00	1.00 – 1.03	-0.04 - -0.02

[Table 2 on page 9]
Allergen
(Component
Number)	Regression Equation	R2	95% CI
Slope
nCyn d
(g216)	y = 0.96	1.00	0.95 – 0.97
rAlt a 1
(m229)	y = 0.96x	0.99	0.96 – 0.99
nAmb a 1
(w230)	y = 0.97x + 0.02	1.00	0.96 – 0.98

--- Page 10 ---
unopened shelf-life of 24 months from the date of manufacture when stored at
2-8°C. For the accelerated study, three lots of component allergens were
stored at 30°C for eight weeks. The same lot stored at 2-8°C was used as
reference. At four weeks and at eight weeks two positive and one negative
control samples (stored human plasma) were tested in duplicate in each
storage condition/lot combination. The results support the manufacture’s
claim of 24 months. Real-time stability studies are underway for these
components and currently support a claim of 13 months.
The stability of the calibration curve, real time, and on-board stability of
ImmunoCAP Specific IgE calibrator are detailed in k100999.
d. Detection limit:
The Limit of Blank (LoB) and the Limit of Detection (LoD) were determined
for each allergen component on the Phadia 250 in alignment with CLSI
EP17-A. The LoB was based on single determinations of 100 negative
samples (blank samples); the LoB was estimated as the 95% percentile of the
distribution. LoD was calculated according to the equation: LoD = LoB + c
β
×SD where SD, the standard deviation, was based on 20 determinations of 3
low positive samples, in total 60 determinations. In data not shown here, the
applicant demonstrated that the Phadia 100 and the Phadia 1000 instruments
had similar LoBs and LoDs for a subset of the allergens below.
Allergen Allergen
LoB LoD
Group component
d202 0.025 0.036
House Dust
d203 0.000 0.010
Mite
d205 0.000 0.009
e94 0.010 0.024
Cat
e220 0.002 0.020
f422 0.004 0.010
f423 0.008 0.066
Peanut f424 0.006 0.029
f352 0.008 0.020
f427 0.007 0.019
Bermuda Grass g216 0.016 0.030
Alternaria w230 0.007 0.018
alternata
10

[Table 1 on page 10]
Allergen
Group	Allergen
component	LoB	LoD
House Dust
Mite	d202	0.025	0.036
	d203	0.000	0.010
	d205	0.000	0.009
Cat	e94	0.010	0.024
	e220	0.002	0.020
Peanut	f422	0.004	0.010
	f423	0.008	0.066
	f424	0.006	0.029
	f352	0.008	0.020
	f427	0.007	0.019
Bermuda Grass	g216	0.016	0.030
Alternaria
alternata	w230	0.007	0.018

--- Page 11 ---
Allergen Allergen
LoB LoD
Group component
Ragweed m229 0.007 0.014
e. Analytical specificity:
Specificity of each allergen was verified through competitive inhibition studies
planned in accordance with CLSI I/LA20-A. Inhibition studies should show an
overall dose dependent decrease of free specific IgE antibodies available to
bind to the ImmunoCAP Allergen. This dose dependent decrease indicates
the presence of antibodies that recognize the allergen; no, or little, decrease in
response indicates that there are no antibodies specific to the allergen. The
specific inhibition demonstrates the presence of immunologically relevant and
reactive allergen bound to the solid phase.
To establish the minimum theoretical response level for the sample (100%
inhibition, “100%”), equal volumes of negative sample and buffer were
premixed and tested with the assay. This should mimic the state where all IgE
antibodies are bound by the added soluble inhibitor (allergen) so that no
specific IgE antibodies are available to bind to the solid phase.
The maximum response level for the sample (0% inhibition, “0%”), is
established by pre-mixing equal volumes of positive sample and buffer and
testing with the assay.
Overall dose dependent inhibition of specific allergens was demonstrated by
premixing 100 µl of positive sample with varying dilutions of allergen
solution (inhibitor). As a control, three unrelated antigens were also tested at
one concentration each in separate experiments.
The mixtures were incubated in a sample tube at room temperature for 1 hour
before being analyzed with the ImmunoCAP Allergen Component according
to the manufacturer’s instructions. The testing was performed in duplicates in
one assay run. Mean values were calculated.
The results of the studies (not shown) demonstrate that the allergens tested are
inhibited by the relevant inhibitor extract in a concentration dependent
fashion; all allergens were able to be inhibited by more than 50%. Most
allergens could be inhibited more than 90% by the highest concentration of
inhibitor (i.e. the least dilute dilution).
Additional inhibition studies were conducted to show that the specific allergens
are not cross-reacting to unrelated allergens. Testing was performed using one
positive sample with three unrelated allergen extracts.
f. Assay cut-off:
11

[Table 1 on page 11]
Allergen
Group	Allergen
component	LoB	LoD
Ragweed	m229	0.007	0.014

--- Page 12 ---
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
Refer to clinical studies.
b. Matrix comparison:
Serum, heparin plasma, and EDTA plasma samples were collected from
patients with clinical history of known specific allergies. These samples were
tested with the ImmunoCap allergen components included in this submission.
This resulted in a range of results (negative and positive) within each sample;
for example, a sample was negative for f423 (peanut rAra h 2) but was
strongly positive for e94 (cat rFel d 1). Recovery of the heparin plasma and
EDTA plasma was acceptable in all positive (≥ 0.35 kU /L) samples. This
A
study suggests that the three sample matrices are interchangeable.
3. Clinical studies:
a. Clinical sensitivity and Specificity:
The performance of all 13 individual allergen components was compared to a
clinical diagnosis of allergy. Atopic samples were obtained from individuals
with a clinical history of allergy-like symptoms upon exposure to an allergen
as diagnosed by a physician and/or clinical symptoms and/or positive skin
prick test to a specific allergen. Information about clinical symptoms and
manifestations was available for all atopic samples. 100 negative samples
(<0.35 kU /L) from healthy non-atopic donors were also tested.
A
House dust mites:
ImmunoCAP Allergen d202, nDer p 1
Clinical Diagnosis
Atopic Non-atopic Total
Positive 56 0 56
nDer p 1(d202) Negative 1 100 101
Total 57 100 157
Sensitivity =98% (95% CI: 90.7 – 99.7%)
Specificity =100%
ImmunoCAP Allergen d203, rDer p 2
Clinical Diagnosis
Atopic Non-atopic Total
Positive 53 0 53
rDer p 2 (d203) Negative 4 100 104
Total 57 100 157
Sensitivity =93% (95% CI: 83.3 – 97.2%)
Specificity =100%
ImmunoCAP Allergen d205,rDer p 10, Tropomyosin
12

[Table 1 on page 12]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
nDer p 1(d202)	Positive	56	0	56
	Negative	1	100	101
	Total	57	100	157

[Table 2 on page 12]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rDer p 2 (d203)	Positive	53	0	53
	Negative	4	100	104
	Total	57	100	157

--- Page 13 ---
Clinical Diagnosis
Atopic Non-atopic Total
Positive 36 0 36
rDer p 10 (d205) Negative 36 100 136
Total 72 100 172
Sensitivity =50% (95% CI: 38.8 – 61.3%
Specificity =100%
Cat:
ImmunoCAP Allergen e94, rFel d 1
Clinical Diagnosis
Atopic Non-atopic Total
Positive 72 0 72
rFel d 1 (e94) Negative 1 100 101
Total 73 100 173
Sensitivity =99% (95% CI: 92.6 – 99.8%)
Specificity =100%
ImmunoCAP Allergen e220, nFel d 2
Clinical Diagnosis
Atopic Non-atopic Total
Positive 34 0 34
nFel d 2 (e220) Negative 39 100 139
Total 73 100 173
Sensitivity =47% (95% CI: 35.6 – 57.9%)
Specificity =100%
Peanut:
ImmunoCAP Allergen f422, rAra h 1
Clinical Diagnosis
Atopic Non-atopic Total
Positive 37 0 37
rAra h 1 (f422) Negative 56 100 156
Total 93 100 193
Sensitivity =40% (95% CI: 30.4 – 50.0%)
Specificity =100%
ImmnuoCAP Allergen f423, rAra h 2
Clinical Diagnosis
Atopic Non-atopic Total
Positive 40 0 40
rAra h 2 (f423) Negative 53 100 153
13

[Table 1 on page 13]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rDer p 10 (d205)	Positive	36	0	36
	Negative	36	100	136
	Total	72	100	172

[Table 2 on page 13]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rFel d 1 (e94)	Positive	72	0	72
	Negative	1	100	101
	Total	73	100	173

[Table 3 on page 13]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
nFel d 2 (e220)	Positive	34	0	34
	Negative	39	100	139
	Total	73	100	173

[Table 4 on page 13]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rAra h 1 (f422)	Positive	37	0	37
	Negative	56	100	156
	Total	93	100	193

[Table 5 on page 13]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rAra h 2 (f423)	Positive	40	0	40
	Negative	53	100	153

--- Page 14 ---
Total 93 100 193
Sensitivity =43% (95% CI: 33.4 – 53.2%)
Specificity =100%
ImmnuoCAP Allergen f424, rAra h 3
Clinical Diagnosis
Atopic Non-atopic Total
Positive 37 0 37
rAra h 3 (f424) Negative 56 100 156
Total 93 100 193
Sensitivity =40% (95% CI: 30.4 – 50.0%)
Specificity =100%
ImmunoCAP Allergen f352, rAra h 8, PR-10
Clinical Diagnosis
Atopic Non-atopic Total
Positive 43 0 43
Negative 50 100 150
rAra h 8 (f352)
Total 93 100 193
Sensitivity =46% (95% CI: 33.4 – 53.2%)
Specificity =100%
ImmnuoCAP Allergen f427, rAra h 9, LTP
Clinical Diagnosis
Atopic Non-atopic Total
Positive 52 0 52
rAra h 9 (f427) Negative 22 100 141
Total 74 100 193
Sensitivity =70% 95% CI: 59.1 – 79.5%)
Specificity =100%
Bermuda grass:
ImmunoCAP Allergen g216, nCyn d 1
Clinical Diagnosis
Atopic Non-atopic Total
Positive 31 0 31
nCyn d 1 (g216) Negative 0 100 100
Total 31 100 131
Sensitivity =100%
Specificity =100%
Alternaria alternata:
14

[Table 1 on page 14]
	Total	93	100	193

[Table 2 on page 14]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rAra h 3 (f424)	Positive	37	0	37
	Negative	56	100	156
	Total	93	100	193

[Table 3 on page 14]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rAra h 8 (f352)	Positive	43	0	43
	Negative	50	100	150
	Total	93	100	193

[Table 4 on page 14]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rAra h 9 (f427)	Positive	52	0	52
	Negative	22	100	141
	Total	74	100	193

[Table 5 on page 14]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
nCyn d 1 (g216)	Positive	31	0	31
	Negative	0	100	100
	Total	31	100	131

--- Page 15 ---
ImmunoCAP Allergen m229, rAlt a 1
Clinical Diagnosis
Atopic Non-atopic Total
Positive 45 0 45
rAlt a 1 (m229) Negative 0 100 100
Total 45 100 145
Sensitivity =100%
Specificity =100%
Ragweed:
ImmunoCAP Allergen w230, nAmb a 1
Clinical Diagnosis
Atopic Non-atopic Total
Positive 34 0 34
nAmb a 1
Negative 0 100 100
(w230)
Total 34 100 134
Sensitivity =100%
Specificity =100%
All studies described above were performed on the Phadia 250 instrument
system. The applicant provided studies to show that the Phadia 100 and
Phadia 1000 instrument system performed similarly to the Phadia 250.
Literature support was provided on allergens with low prevalence and %
sensitivity as shown below:
Specific
Allergen
Allergen Prevalence Clinical
Clinical Literature Cited
Name Found Sensitivity
Sensitivity
(%)
rDer p 10 d1 1) Jaén A et al. European 1) ECRHS 2) Mite allergic
d205 House Community Respiratory Health 12687 subjects patients from
(50%) dust Survey. Specific sensitization to from 34 Austria (n=56)
mite common allergens and pulmonary centres in 15 France N(55)
function in the European countries. Italy n=(67)
Community Respiratory Health Prevalence of Sweden (n=31)
Survey. sensitization Der p 10 positive
Clin Exp Allergy. 2002 to mite: in 18%, 9%,10%
Dec;32(12):1713-9. Women; and 18%
16.8% Men; respectively
2) Weghofer M et al. Variability 23.5%
of IgE reactivity profiles among 3) 90 mite
European mite allergic patients. allergic patients
Eur J Clin Invest 2008;38 (12): in Colombia. Der
959-65. p 10 positive
15

[Table 1 on page 15]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
rAlt a 1 (m229)	Positive	45	0	45
	Negative	0	100	100
	Total	45	100	145

[Table 2 on page 15]
		Clinical Diagnosis		
		Atopic	Non-atopic	Total
nAmb a 1
(w230)	Positive	34	0	34
	Negative	0	100	100
	Total	34	100	134

[Table 3 on page 15]
Specific
Allergen
Clinical
Sensitivity
(%)	Allergen
Name	Literature Cited	Prevalence
Found	Clinical
Sensitivity
rDer p 10
d205
(50%)	d1
House
dust
mite	1) Jaén A et al. European
Community Respiratory Health
Survey. Specific sensitization to
common allergens and pulmonary
function in the European
Community Respiratory Health
Survey.
Clin Exp Allergy. 2002
Dec;32(12):1713-9.
2) Weghofer M et al. Variability
of IgE reactivity profiles among
European mite allergic patients.
Eur J Clin Invest 2008;38 (12):
959-65.	1) ECRHS
12687 subjects
from 34
centres in 15
countries.
Prevalence of
sensitization
to mite:
Women;
16.8% Men;
23.5%	2) Mite allergic
patients from
Austria (n=56)
France N(55)
Italy n=(67)
Sweden (n=31)
Der p 10 positive
in 18%, 9%,10%
and 18%
respectively
3) 90 mite
allergic patients
in Colombia. Der
p 10 positive

--- Page 16 ---
Specific
Allergen
Allergen Prevalence Clinical
Clinical Literature Cited
Name Found Sensitivity
Sensitivity
(%)
16.7%
3) Jiménez S. et al. IgE antibody
responses to recombinant 4) 60 mite
allergens of Blomia tropicalis and allergic patients
Dermatophagoides pteronyssinus in Spain; Der p
in a tropical environment. 10 positive in
Allergy and Clinical Immunology 32% of 30
International Volume 19, Issue 6, patients with both
November 2007, Pages 233-238 mite and seafood
symptoms and in
4) Boquete M. et al. Seafood 0% of 30 patients
hypersensitivity in mite sensitized with only mite
individuals: is tropomyosin the symptoms
only responsible allergen?
Annals of Allergy, Asthma &
Immunology, Volume 106, Issue
3, March 2011, Pages 223-229
n Fel d 2 e1 1) Spitzauer S. et al. IgE cross- 1) ECRHS 1) 200 animal
e220 Cat reactivities against albumins in 12687 subjects allergic patients;
(47%) patients allergic to animals. from 34 Cat albumin (Fel
J Allergy Clin centres in 15 d 2) positive in
Immunol 1995;96(6 Pt 1): 951-9 countries. 26% of patients
Prevalence of 2) 2 groups of cat
2) Hilger C. et al. Allergic cross- sensitization allergic patients
reactions between cat and pig to cat: (n=39 and n=39)
serum albumin. Study at the Women ; 9.3 Fel d 2 positive in
protein and DNA levels. % Men; 9.5% 14% and 23%
Allergy 1997;52(2):179-87 1 group (n=10)
allergic both to
3) van Ree R. et al. Purified cat and pork ;
natural and recombinant Fel d 1 Fel d 2 positive in
and cat albumin in in vitro 100%
diagnostics for cat allergy.
J Allergy Clin Immunol 3) 509 cat
1999;104(6):1223-30 sensitized
patients ;
4) Cabanas, R., M. C. Lopez- Fel d 2 positive
Serrano, et al. "Importance of in 16.7%
albumin in cross-reactivity among
cat, dog and horse allergens." 4) 117 cat
Journal of Investigational allergic patients;
Allergology & Clinical Fel d 2 positive in
Immunology 2000; 10(2): 71-77. 22%
16

[Table 1 on page 16]
Specific
Allergen
Clinical
Sensitivity
(%)	Allergen
Name	Literature Cited	Prevalence
Found	Clinical
Sensitivity
		3) Jiménez S. et al. IgE antibody
responses to recombinant
allergens of Blomia tropicalis and
Dermatophagoides pteronyssinus
in a tropical environment.
Allergy and Clinical Immunology
International Volume 19, Issue 6,
November 2007, Pages 233-238
4) Boquete M. et al. Seafood
hypersensitivity in mite sensitized
individuals: is tropomyosin the
only responsible allergen?
Annals of Allergy, Asthma &
Immunology, Volume 106, Issue
3, March 2011, Pages 223-229		16.7%
4) 60 mite
allergic patients
in Spain; Der p
10 positive in
32% of 30
patients with both
mite and seafood
symptoms and in
0% of 30 patients
with only mite
symptoms
n Fel d 2
e220
(47%)	e1
Cat	1) Spitzauer S. et al. IgE cross-
reactivities against albumins in
patients allergic to animals.
J Allergy Clin
Immunol 1995;96(6 Pt 1): 951-9
2) Hilger C. et al. Allergic cross-
reactions between cat and pig
serum albumin. Study at the
protein and DNA levels.
Allergy 1997;52(2):179-87
3) van Ree R. et al. Purified
natural and recombinant Fel d 1
and cat albumin in in vitro
diagnostics for cat allergy.
J Allergy Clin Immunol
1999;104(6):1223-30
4) Cabanas, R., M. C. Lopez-
Serrano, et al. "Importance of
albumin in cross-reactivity among
cat, dog and horse allergens."
Journal of Investigational
Allergology & Clinical
Immunology 2000; 10(2): 71-77.	1) ECRHS
12687 subjects
from 34
centres in 15
countries.
Prevalence of
sensitization
to cat:
Women ; 9.3
% Men; 9.5%	1) 200 animal
allergic patients;
Cat albumin (Fel
d 2) positive in
26% of patients
2) 2 groups of cat
allergic patients
(n=39 and n=39)
Fel d 2 positive in
14% and 23%
1 group (n=10)
allergic both to
cat and pork ;
Fel d 2 positive in
100%
3) 509 cat
sensitized
patients ;
Fel d 2 positive
in 16.7%
4) 117 cat
allergic patients;
Fel d 2 positive in
22%

--- Page 17 ---
Specific
Allergen
Allergen Prevalence Clinical
Clinical Literature Cited
Name Found Sensitivity
Sensitivity
(%)
rAra h 1 f13 1) Branum AM, Lukacs SL. Food 1) NHANES: 2) Peanut allergic
f422 Peanut allergy among children in the Prevalence of children in
(40%) United States peanut Sweden (n=58);
Pediatrics. 2009 sensitized Positive to:
Dec;124(6):1549-55. Epub 2009 children in Ara h 1; 48%
Nov 16. USA
estimated to 3) Peanut allergic
2) Asarnoj A. et al. IgE to peanut 9% patients in France
allergen components: relation to (n=166)
peanut symptoms and pollen Positive to:
sensitization in 8-year-olds. Ara h 1;75%
Allergy 2010;65: 1189-1195
4) Peanut
3) Codreanu et al. A Novel Allergic patients
Immunoassay using recombinant from 3 countries
allergens simplifies peanut allergy Spain (n=50)
diagnosis. USA (n=30),
Int Arch Allergy Immunol Sweden (n=35)
2011;154:216–226 Positive to :
Ara h 1; 30%,
4) Vereda A. et al. Peanut allergy: 80%, 62,9%
Clinical and immunologic respectively
differences among patients from 3
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line; DOI:
10.1016/j.jaci.2010.09.010)
r Ar a h f13 1) Branum AM, Lukacs SL. Food 1) NHANES: 2) Peanut allergic
2f423 Peanut allergy among children in the Prevalence of children in
(43%) United States peanut Sweden (n=58);
Pediatrics. 2009 sensitized Positive to:
Dec;124(6):1549-55. Epub 2009 children in Ara h 2; 78%
Nov 16. USA
estimated to 3) Peanut allergic
2) Asarnoj A. et al. IgE to peanut 9% patients in France
allergen components: relation to (n=166)
peanut symptoms and pollen Positive to:
sensitization in 8-year-olds. Ara h 2; 96%
Allergy 2010;65: 1189-1195
4) Peanut
3) Codreanu et al. A Novel Allergic patients
Immunoassay using recombinant from 3 countries
allergens simplifies peanut allergy Spain (n=50)
diagnosis. Int Arch Allergy USA (n=30),
Immunol 2011;154:216–226 Sweden (n=35)
17

[Table 1 on page 17]
Specific
Allergen
Clinical
Sensitivity
(%)	Allergen
Name	Literature Cited	Prevalence
Found	Clinical
Sensitivity
rAra h 1
f422
(40%)	f13
Peanut	1) Branum AM, Lukacs SL. Food
allergy among children in the
United States
Pediatrics. 2009
Dec;124(6):1549-55. Epub 2009
Nov 16.
2) Asarnoj A. et al. IgE to peanut
allergen components: relation to
peanut symptoms and pollen
sensitization in 8-year-olds.
Allergy 2010;65: 1189-1195
3) Codreanu et al. A Novel
Immunoassay using recombinant
allergens simplifies peanut allergy
diagnosis.
Int Arch Allergy Immunol
2011;154:216–226
4) Vereda A. et al. Peanut allergy:
Clinical and immunologic
differences among patients from 3
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line; DOI:
10.1016/j.jaci.2010.09.010)	1) NHANES:
Prevalence of
peanut
sensitized
children in
USA
estimated to
9%	2) Peanut allergic
children in
Sweden (n=58);
Positive to:
Ara h 1; 48%
3) Peanut allergic
patients in France
(n=166)
Positive to:
Ara h 1;75%
4) Peanut
Allergic patients
from 3 countries
Spain (n=50)
USA (n=30),
Sweden (n=35)
Positive to :
Ara h 1; 30%,
80%, 62,9%
respectively
r Ar a h
2f423
(43%)	f13
Peanut	1) Branum AM, Lukacs SL. Food
allergy among children in the
United States
Pediatrics. 2009
Dec;124(6):1549-55. Epub 2009
Nov 16.
2) Asarnoj A. et al. IgE to peanut
allergen components: relation to
peanut symptoms and pollen
sensitization in 8-year-olds.
Allergy 2010;65: 1189-1195
3) Codreanu et al. A Novel
Immunoassay using recombinant
allergens simplifies peanut allergy
diagnosis. Int Arch Allergy
Immunol 2011;154:216–226	1) NHANES:
Prevalence of
peanut
sensitized
children in
USA
estimated to
9%	2) Peanut allergic
children in
Sweden (n=58);
Positive to:
Ara h 2; 78%
3) Peanut allergic
patients in France
(n=166)
Positive to:
Ara h 2; 96%
4) Peanut
Allergic patients
from 3 countries
Spain (n=50)
USA (n=30),
Sweden (n=35)

--- Page 18 ---
Specific
Allergen
Allergen Prevalence Clinical
Clinical Literature Cited
Name Found Sensitivity
Sensitivity
(%)
Positive to :
4) Vereda A. et al. Peanut allergy: Ara h 2; 42%,
Clinical and immunologic 90%, 74,3%
differences among patients from 3 respectively
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line ; DOI:
10.1016/j.jaci.2010.09.010)
rAra h 3 f13 1) Branum AM, Lukacs SL. Food 1) NHANES: 2) Peanut allergic
f424 Peanut allergy among children in the Prevalence of children in
(40%) United States peanut Sweden (n=58);
Pediatrics. 2009 sensitized Positive to:
Dec;124(6):1549-55. Epub 2009 children in Ara h 3; 41%
Nov 16. USA
estimated to 3) Peanut allergic
2) Asarnoj A. et al. IgE to peanut 9% patients in France
allergen components: relation to (n=166)
peanut symptoms and pollen Positive to:
sensitization in 8-year-olds. Ara h 3; 61%
Allergy 2010;65: 1189-1195
4) Peanut
3) Codreanu et al. A Novel Allergic patients
Immunoassay using recombinant from 3 countries
allergens simplifies peanut allergy Spain (n=50)
diagnosis. USA (n=30),
Int Arch Allergy Immunol Sweden (n=35)
2011;154:216–226 Positive to :
Ara h 3:
4) Vereda A. et al. Peanut allergy: 16%,56,7%,
Clinical and immunologic 37,1%
differences among patients from 3 respectively
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line; DOI:
10.1016/j.jaci.2010.09.010)
rAra h 8 f13 1) Branum AM, Lukacs SL. Food 1) NHANES: 2) Peanut and
f352 Peanut allergy among children in the Prevalence of birch allergic
(46%) United States peanut patients in
Pediatrics. 2009 sensitized Germany (n=20)
Dec;124(6):1549-55. Epub 2009 children in Positive to:
Nov 16. USA Ara h 8; 85 %
estimated to
2) Mittag D. et al. Ara h 8, a Bet v 9% 3) Peanut allergic
1-homologous allergen from children in
peanut, is a major allergen in Sweden (n=58);
18

[Table 1 on page 18]
Specific
Allergen
Clinical
Sensitivity
(%)	Allergen
Name	Literature Cited	Prevalence
Found	Clinical
Sensitivity
		4) Vereda A. et al. Peanut allergy:
Clinical and immunologic
differences among patients from 3
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line ; DOI:
10.1016/j.jaci.2010.09.010)		Positive to :
Ara h 2; 42%,
90%, 74,3%
respectively
rAra h 3
f424
(40%)	f13
Peanut	1) Branum AM, Lukacs SL. Food
allergy among children in the
United States
Pediatrics. 2009
Dec;124(6):1549-55. Epub 2009
Nov 16.
2) Asarnoj A. et al. IgE to peanut
allergen components: relation to
peanut symptoms and pollen
sensitization in 8-year-olds.
Allergy 2010;65: 1189-1195
3) Codreanu et al. A Novel
Immunoassay using recombinant
allergens simplifies peanut allergy
diagnosis.
Int Arch Allergy Immunol
2011;154:216–226
4) Vereda A. et al. Peanut allergy:
Clinical and immunologic
differences among patients from 3
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line; DOI:
10.1016/j.jaci.2010.09.010)	1) NHANES:
Prevalence of
peanut
sensitized
children in
USA
estimated to
9%	2) Peanut allergic
children in
Sweden (n=58);
Positive to:
Ara h 3; 41%
3) Peanut allergic
patients in France
(n=166)
Positive to:
Ara h 3; 61%
4) Peanut
Allergic patients
from 3 countries
Spain (n=50)
USA (n=30),
Sweden (n=35)
Positive to :
Ara h 3:
16%,56,7%,
37,1%
respectively
rAra h 8
f352
(46%)	f13
Peanut	1) Branum AM, Lukacs SL. Food
allergy among children in the
United States
Pediatrics. 2009
Dec;124(6):1549-55. Epub 2009
Nov 16.
2) Mittag D. et al. Ara h 8, a Bet v
1-homologous allergen from
peanut, is a major allergen in	1) NHANES:
Prevalence of
peanut
sensitized
children in
USA
estimated to
9%	2) Peanut and
birch allergic
patients in
Germany (n=20)
Positive to:
Ara h 8; 85 %
3) Peanut allergic
children in
Sweden (n=58);

--- Page 19 ---
Specific
Allergen
Allergen Prevalence Clinical
Clinical Literature Cited
Name Found Sensitivity
Sensitivity
(%)
patients with combined birch Positive to:
pollen and peanut allergy. Ara h 8; 14 %
J Allergy Clin Immunol
2004;114:1410-1417 4) Peanut
Allergic patients
3) Asarnoj A. et al. IgE to peanut from 3 countries
allergen components: relation to Spain (n=50)
peanut symptoms and pollen USA (n=30),
sensitization in 8-year-olds. Sweden (n=35)
Allergy 2010;65: 1189-1195 Positive to :
Ara h 8: 2%,
4) Vereda A. et al. Peanut allergy: 19,1%, 65,7%
Clinical and immunologic
differences among patients from 3
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line; DOI:
10.1016/j.jaci.2010.09.010)
b. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
The expected value is negative (< 0.35 kU /L) for a specific allergen in a non-
A
allergic person. The manufacturer recommends a cut-off of 0.35 kU /L. Each
A
laboratory should establish its own expected range of values.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
19

[Table 1 on page 19]
Specific
Allergen
Clinical
Sensitivity
(%)	Allergen
Name	Literature Cited	Prevalence
Found	Clinical
Sensitivity
		patients with combined birch
pollen and peanut allergy.
J Allergy Clin Immunol
2004;114:1410-1417
3) Asarnoj A. et al. IgE to peanut
allergen components: relation to
peanut symptoms and pollen
sensitization in 8-year-olds.
Allergy 2010;65: 1189-1195
4) Vereda A. et al. Peanut allergy:
Clinical and immunologic
differences among patients from 3
different geographic regions (J
Allergy Clin Immunol 2011 in
press on line; DOI:
10.1016/j.jaci.2010.09.010)		Positive to:
Ara h 8; 14 %
4) Peanut
Allergic patients
from 3 countries
Spain (n=50)
USA (n=30),
Sweden (n=35)
Positive to :
Ara h 8: 2%,
19,1%, 65,7%